Massive Bio

Istanbul, Turkey · ≈110 employees · massivebio.com

Massive Bio is an AI-driven health-tech company based in New York, founded in 2014. It connects cancer patients worldwide to bio-pharmaceutical clinical trials, removing barriers related to location, income, or cancer type. The company operates in 17 countries across North America, Europe, and LATAM, using proprietary AI technology to match patients with suitable oncology trials. The core services offered by Massive Bio include AI-powered clinical trial matching, patient identification, virtual pre-screening, and concierge enrollment enablement for oncology and hematology patients, all provided free of charge. The company also features a big data platform that enhances the clinical trial enrollment process for pharmaceutical companies and contract research organizations (CROs). Additionally, Massive Bio provides the Patient Connect portal, a digital platform that personalizes access to cancer clinical trials globally, and tools for virtual tumor board collaboration among oncologists and experts. Massive Bio collaborates with numerous pharmaceutical companies, CROs, and healthcare institutions to optimize patient recruitment and drug commercialization. The company partners with organizations like the American Cancer Society and biotech firms such as Inocras to enhance access to clinical trials and integrate genomic insights. Its mission is to empower individuals with equal access to cancer clinical trials through innovative services and technology.